Support from inpatient to outpatient

TAVNEOS® (avacopan) is the only oral adjunctive treatment that is FDA approved for adults with severe active GPA or MPA.

Step 1: Inpatient delivery

Order TAVNEOS® to your patient's inpatient hospital pharmacy through our Specialty Distributor network.

- Offered as a 5-day supply (wholesale acquisition cost (WAC) is $2,757.90)
- TAVNEOS® will typically be delivered the next business day

Specialty Distributors

Reach out to one of these Specialty Distributors directly to order TAVNEOS® for the inpatient pharmacy.

Cardinal Health Specialty Pharmaceutical Distribution (SPD)
- Phone: (866) 476-1340
- Email: GMB-SPD-CSOrderEntry@cardinalhealth.com
- Online: orderexpress.cardinalhealth.com

ASD Healthcare (Cencora)
- Phone: (800) 746-6273
- Fax: (800) 547-9413
- Email: service@asdhealthcare.com
- Online: asdhealthcare.com

McKesson Plasma and Biologics
- Phone: (877) 625-2566
- Fax: (888) 752-7626
- Email: mpborders@mckesson.com
- Online: connect.mckesson.com

Step 2: Outpatient transition

Avoid therapy disruption when transitioning to the outpatient setting by requesting the TAVNEOS® Quick Start Program* as soon as possible prior to discharge.

- Complete the Quick Start section of the Patient Enrollment Form, including office "Contact Name" and "Contact's Phone"
- Fax the completed Patient Enrollment Form to a Specialty Pharmacy (fax and contact information are listed at the top of the form)
- Once approved, eligible patients or their authorized contact will be contacted to set up home delivery
- The Specialty Pharmacy will continue to help advance the insurance approval process

Scan or visit **TAVNEOSPro.com** to download the Patient Enrollment Form

*The TAVNEOS® Quick Start Program is available to adult patients whose diagnosis is aligned to the FDA-approved indication for TAVNEOS®. Additional eligibility criteria apply.

Product Information

Product

Products not shown at actual size

10 mg, opaque, yellow and orange capsule with CCX168 printed in black

NDC	73556-168-01 (180 count) 73556-168-02 (30 count)
Strength	10 mg
Form	Capsule
Dosing	3 capsules by mouth, twice daily, with food

For questions, call the TAVNEOS® Team

at 1-833-TAVNEOS (**1-833-828-6367**)
Monday through Friday from 8 am to 8 pm ET

To request a representative,
visit TAVNEOSPro.com/contact

INDICATION

TAVNEOS® (avacopan) is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS® does not eliminate glucocorticoid use.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS

Serious hypersensitivity to avacopan or to any of the excipients.

Please see additional Important Safety Information on the next page.

TAVNEOS® (avacopan)

IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS

Hepatotoxicity: Serious cases of hepatic injury have been observed in patients taking TAVNEOS®, including life-threatening events. Obtain liver test panel before initiating TAVNEOS®, every 4 weeks after start of therapy for 6 months and as clinically indicated thereafter. Monitor patients closely for hepatic adverse reactions, and consider pausing or discontinuing treatment as clinically indicated (refer to section 5.1 of the Prescribing Information). TAVNEOS® is not recommended for patients with active, untreated, and/or uncontrolled chronic liver disease (e.g., chronic active hepatitis B, untreated hepatitis C, uncontrolled autoimmune hepatitis) and cirrhosis. Consider the risks and benefits before administering this drug to a patient with liver disease.

Serious Hypersensitivity Reactions: Cases of angioedema occurred in a clinical trial, including 1 serious event requiring hospitalization. Discontinue immediately if angioedema occurs and manage accordingly. TAVNEOS® must not be readministered unless another cause has been established.

Hepatitis B Virus (HBV) Reactivation: Hepatitis B reactivation, including life-threatening hepatitis B, was observed in the clinical program. Screen patients for HBV. For patients with evidence of prior infection, consult with physicians with expertise in HBV and monitor during TAVNEOS® therapy and for 6 months following. If patients develop HBV reactivation, immediately discontinue TAVNEOS® and concomitant therapies associated with HBV reactivation, and consult with experts before resuming.

Serious Infections: Serious infections, including fatal infections, have been reported in patients receiving TAVNEOS®. The most common serious infections reported in the TAVNEOS® group were pneumonia and urinary tract infections. Avoid use of TAVNEOS® in patients with active, serious infection, including localized infections. Consider the risks and benefits before initiating TAVNEOS® in patients with chronic infection, at increased risk of infection, or who have been to places where certain infections are common.

ADVERSE REACTIONS

The most common adverse reactions (≥5% of patients and higher in the TAVNEOS® group vs. prednisone group) were nausea, headache, hypertension, diarrhea, vomiting, rash, fatigue, upper abdominal pain, dizziness, blood creatinine increased, and paresthesia.

DRUG INTERACTIONS

Avoid coadministration of TAVNEOS® with strong and moderate CYP3A4 enzyme inducers. Reduce TAVNEOS® dose when coadministered with strong CYP3A4 enzyme inhibitors to 30 mg once daily. Monitor for adverse reactions and consider dose reduction of certain sensitive CYP3A4 substrates.

TAVNEOS® is available as a 10 mg capsule.

Please see Full Prescribing Information and Medication Guide for TAVNEOS®.

To report a suspected adverse event, call 1-833-828-6367. You may report to the FDA directly by visiting www.fda.gov/medwatch or calling 1-800-332-1088.

Reference: TAVNEOS® [package insert]. Cincinnati, OH: Amgen Inc.

TAVNEOS® (avacopan)

AMGEN